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Abstract
Background: Prescribing patterns for stroke prevention in atrial fibrillation (AF) 
patients evolved with approval of non- Vitamin K antagonist oral anticoagulants 
(NOACs) over time.
Objectives: To assess changes in anticoagulant prescription patterns in various geo-
graphical regions upon first approval of a NOAC and to analyze the evolution of oral 
anticoagulants (OACs) use over time in relation to CHA2DS2- VASc and HAS- BLED 
risk profiles.
Methods: Global Registry on Long- Term Oral Antithrombotic Treatment in Patients 
with Atrial Fibrillation (GLORIA- AF) Phases II and III reported data on antithrombotic 
therapy for patients with newly diagnosed AF and ≥1 stroke risk factor. We focused 
on sites enrolling patients in both phases and reported treatment patterns for the 
first 4 years after initial NOAC approval.
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1  | INTRODUC TION
Atrial fibrillation (AF) is the most common cardiac arrhythmia, with 
both incidence and prevalence increasing with age. Nonvalvular AF 
is associated with a fivefold increase in risk of stroke. Therefore, 
stroke prevention is the cornerstone of the holistic approach to 
AF management. Currently, when oral anticoagulation (OAC) is in-
dicated for stroke prevention in patients with AF, non- Vitamin K 
antagonist oral anticoagulants (NOACs) are recommended in pref-
erence to Vitamin K antagonists (VKAs).1 In contrast, when NOACs 
were introduced and adopted into practice, clinical guidelines were 
still assessing results from pivotal trials. Since then, the rationale 
for using NOACs has changed. It is challenging to measure temporal 
trends of global prescription patterns, however, because the timing 
of NOAC approval varied across countries and prescription patterns 
can change rapidly as uptake of a new agent increases. Moreover, 
use of a particular OAC may reflect the manner in which physicians 
interpret stroke and bleeding risk scores, which have also been in-
corporated variably into clinical practice guidelines. Published de-
scriptions of global NOAC uptake have not consistently accounted 
for these variables, overlooking distinctions based on the local 
availability of NOACs for clinical use. Therefore, results of such 
analyses are affected by the distribution of countries included in 
the evaluation.
The specific design of the large, prospective, global registry 
Global Registry on Long- Term Oral Antithrombotic Treatment in 
Patients with Atrial Fibrillation (GLORIA- AF) Phases II and III pro-
vides an opportunity to assess temporal changes over time on a 
global scale. Enrolment for Phases II and III continued from 2011 to 
2016 allowing for assessment of changes in practice patterns in a 
large number of patients over more than 4 years.
This report is based on baseline data, including antithrom-
botic prescriptions for stroke prevention in patients with newly 
diagnosed AF enrolled in Phases II and III of GLORIA- AF. We as-
sessed temporal changes in antithrombotic prescription patterns 
within specific geographical regions, starting from initial NOAC 
approval. We also analyzed changes in types of OAC prescribed 
in relation to CHA2DS2- VASc (heart failure, hypertension, age 
≥75 years, diabetes, stroke/transient ischemic attack, vascular dis-
ease, age 65- 74 years, sex category) and HAS- BLED (hypertension, 
abnormal renal/liver function, stroke, bleeding history or predis-
position, labile international normalized ratio, elderly [>65 years], 
drugs or alcohol concomitantly) risk scores during each year of 
enrolment.
2  | METHODS
The design of GLORIA- AF (https://clini caltr ials.gov/ct2/home; 
trial registration numbers NCT01468701, NCT01671007, and 
NCT01937377) has been previously reported.2 A signed patient 
informed consent form was obtained before enrolment. The study 
protocol is concordant with the ethical guidelines of the 1975 
Declaration of Helsinki.
The GLORIA- AF study collected data in 44 countries regarding 
routine clinical practice for patients with AF diagnosed <3 months 
before the baseline visit (4.5 months in Latin America), to evaluate 
characteristics that influenced choice of antithrombotic treatment 
and clinical outcomes. GLORIA- AF was conducted in three phases 
(Figure 1A,B). Phase I was before NOACs became available for 
stroke prevention in AF. In Phase I, a cross- sectional approach was 
implemented. Phase II began when dabigatran etexilate (dabigatran) 
was approved in each participating country. During Phase II, baseline 
characteristics of all enrolled patients were collected, and those pre-
scribed dabigatran were followed for 2 years. Phase III began once 
relevant baseline characteristics of patients initiating dabigatran and 
Results: From GLORIA- AF Phases II and III, 27 432 patients were eligible for this 
analysis. When contrasting the first year with the fourth year of enrolment, the pro-
portion of NOAC prescriptions increased in Asia from 29.2% to 60.8%, in Europe 
from 53.4% to 75.8%, in North America from 49.0% to 73.9% and in Latin America 
from 55.7% to 71.1%. The proportion of Vitamin K antagonists (VKAs) use decreased 
across all regions over time, in Asia from 26.0% to 9.8%, in Europe from 35.5% to 
16.8%, in North America from 28.9% to 12.1%, and in Latin America from 32.4% to 
17.8%. In the multivariable analysis, factors associated with NOAC prescription were 
as follows: enrolment year, type of site, region, stroke and bleeding risk scores, and 
type and categorization of AF.
Conclusions: During 4 years after the approval of the first NOAC, NOAC use in-
creased, while VKA use decreased, across all regions.
K E Y W O R D S
atrial fibrillation, bleeding risk, GLORIA- AF, oral anticoagulants, stroke risk
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VKA in Phase II showed substantial overlap, as measured by com-
parison of propensity score distributions. During Phase III, follow- up 
data were collected for up to 3 years regardless of prescribed anti-
thrombotic therapy.2
Adults with nonvalvular AF and ≥1 CHA2DS2- VASc risk factor 
score for stroke were included. Stroke and bleeding risks were 
assessed using the CHA2DS2- VASc and HAS- BLED risk scores.
3,4 
Patients were managed according to local practice. This report 
includes regions and sites enrolling patients during Phases II and 
III.
Standard electronic case reports forms (eCRFs) were used to 
collect patients' baseline characteristics and follow- up observation 
F I G U R E  1   (A) Enrolment period 
in Phases II and III of the GLORIA- AF 
registry per country in calendar dates. (B) 
Enrolment period in Phases II and III of the 
GLORIA- AF registry per country in years 
after NOAC availability
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data. Baseline therapy was the treatment prescribed for long- term 
anticoagulation subsequent to the diagnosis of AF and recorded at 
the baseline visit.
Time zero in a participating country was set to the date of the base-
line visit for the first patient in each country. The first year of enrol-
ment for a participating country was the first year after time zero in 
that country. Most countries continued enrolment for up to 4 years. 
In this paper, we classify newly enrolled patients according to which 
prescribed treatment they received at their baseline visit, by year of 
enrolment.
2.1 | Statistical analysis
Treatment patterns are presented as a percentage of patients pre-
scribed NOAC, VKA, or no OAC in each of the 4 years of enrolment, 
overall and by region. Categorical variables are reported as absolute 
frequencies and percentages, and continuous variables are summa-
rized by median (Q1, Q3). Baseline characteristics were described 
by categorization of patients with AF according to stroke prevention 
treatment (NOAC, VKA, no OAC) and year of enrolment (first year ver-
sus last year, ie, Year 4), as well as by CHA2DS2- VASc and HAS- BLED 
risk scores. For each treatment, standardized differences were in-
cluded to compare baseline characteristics between the last year and 
first year of enrolment.5
Factors associated with OAC prescription patterns over time 
were evaluated using log- binomial regression models, providing 
estimates of relative probability for NOAC prescription (vs. VKA 
prescription). Both univariate and multivariable log- binomial re-
gression analyses were fit to evaluate the crude as well as ad-
justed probability ratios together with 95% confidence intervals 
(CIs).
Missing data were imputed using multiple imputation. The impu-
tation model was constructed with 56 baseline patient characteristic 
variables including those used in the multivariable analyses. The COPY 
method was used to obtain approximate maximum likelihood estimates 
when log- binomial models failed to converge.6 Statistical analyses were 
performed using SAS version 9.4 (SAS Institute, Inc, Cary, NC).
3  | RESULTS
There were 27 432 eligible patients who enrolled in GLORIA- AF 
during Phases II and III and who qualified to be included in this 
F I G U R E  2   Temporal trends of antithrombotic therapy prescription globally. NOAC, non- Vitamin K antagonist oral anticoagulants; OAC, 
oral anticoagulation; VKA, Vitamin K antagonists
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analysis. Of 8969 patients who enrolled in the first year, 46.6% 
were prescribed NOAC, 31.9% were prescribed VKA, and 21.5% 
were prescribed no OAC. Of 4388 patients enrolled in the fourth 
year, 71.6% received NOAC, 14.1% received VKA, and 14.3% re-
ceived no OAC (Figure 2). A similar trend in treatment pattern over 
time, ie, increase in NOAC and decrease in VKA, was observed 
for Europe and North America. From the third to fourth year, an 
increase in NOAC prescriptions and a decrease in VKA or no OAC 
prescription was reported in Asia (Figure 3). The prevalence of 
non- OAC slightly decreased from Years 1- 4, except Latin America 
(Figure 2).
Baseline characteristics of patients prescribed NOAC by region 
are summarized in Table 1. Paroxysmal AF was less prevalent in 
patients with NOAC during the first year of enrolment than in pa-
tients with NOAC during the last year of enrolment in Europe, North 
America, and Latin America. The standardized differences for stroke 
and bleeding risk scores (CHA2DS2- VASc and HAS- BLED) between 
the last and first year for NOAC patients were small in Europe, North 
America, and Latin America (less than 0.1).
Baseline characteristics of patients prescribed VKA by region are 
shown in Table 2. The standardized differences for CHA2DS2- VASc 
were small between the patients enrolled during the last and first year 
in North America, while they were more than 0.1 in Europe, Asia and 
Latin America. The standardized differences for HAS- BLED were more 
than 0.1 between last and first year in Asia, North America, and Latin 
America.
Prescription of oral antithrombotic treatment by region is pre-
sented in Table 3 and Figure 3. A decrease in no OAC use includ-
ing acetylsalicylic acid (ASA) was reported in Asia between the 
third and fourth year of enrolment. An increase in NOAC use and 
decrease in VKA and no OAC use including ASA was present in 
Europe and North America. An increase in NOAC and a decrease 
in VKA were reported between second and fourth year in Latin 
America.
3.1 | Factors associated with NOAC prescription in 
phases II and III
Results from univariate analyses are presented in Table 4. In the 
multivariable log- binomial regression analysis, factors strongly as-
sociated with increased prescription of NOAC were as follows: en-
rolment year, type of site (higher probability outside of a university 
hospital, such as GP/primary care, specialist office, community hos-
pital, and other), and region (higher prescription probability in North 
America compared with Europe) (Table 4).
Factors associated with decreased prescription of NOAC were 
the following: HAS- BLED score ≥3 (compared with HAS- BLED 
score <3), categorization of AF (lower probability of symptomatic 
AF compared with asymptomatic AF), CHA2DS2- VASc score ≥2 
(compared with CHA2DS2- VASc score <2), and type of AF (lower 
probability of persistent or permanent AF compared with parox-
ysmal AF) (Table 4).
3.2 | Prescription of antithrombotics over time by 
CHA2DS2- VASc score class
Regional patterns of prescription of antithrombotics over time by 
CHA2DS2- VASc score class are presented in Table S1.
In the first year after approval, 32.5% of those with CHA2DS2- 
VASc scores ≥2 received NOACs in Asia. Corresponding propor-
tions for patients in Europe, North America, and Latin America were 
53.5%, 49.6%, and 56.2%. In the fourth year after approval, 67.1% 
of patients with CHA2DS2- VASc scores ≥2 received NOACs in Asia. 
Corresponding proportions for patients in Europe, North America, 
and Latin America were 75.7%, 75.4%, and 70.4%.
Let interval change denote the change between Year 4 and Year 
1 in prescription rate. The interval changes in those with CHA2DS2- 
VASc scores ≥2 who received NOACs in Asia were +34.6%. The 
F I G U R E  3   Temporal trends of antithrombotic therapy prescription by region. NOAC, non- Vitamin K antagonist oral anticoagulants; OAC, 
oral anticoagulation; VKA, Vitamin K antagonists
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TA B L E  3   Prescription of oral antithrombotic treatment over time by region
Year 1 Year 2 Year 3 Year 4 Total
Region: Asia
Number of patients 2284 (100.0) 1336 (100.0) 1396 (100.0) 937 (100.0) 5953 (100.0)
NOAC (N, %) 666 (29.2) 619 (46.3) 527 (37.8) 570 (60.8) 2382 (40.0)
On NOACs standard dose (N, %)
Yes 214 (9.4) 239 (17.9) 204 (14.6) 224 (23.9) 881 (14.8)
No 452 (19.8) 380 (28.4) 323 (23.1) 346 (36.9) 1501 (25.2)
On NOACs reduced dose (N, %)
Yes 452 (19.8) 380 (28.4) 323 (23.1) 346 (36.9) 1501 (25.2)
No 214 (9.4) 239 (17.9) 204 (14.6) 224 (23.9) 881 (14.8)
VKA (N, %) 594 (26.0) 266 (19.9) 330 (23.6) 92 (9.8) 1282 (21.5)
No OAC (N, %) 1024 (44.8) 451 (33.8) 539 (38.6) 275 (29.3) 2289 (38.5)
ASA (N, %) 522 (22.9) 251 (18.8) 313 (22.4) 150 (16.0) 1236 (20.8)
Antiplts other than ASA (N, %) 34 (1.5) 22 (1.6) 35 (2.5) 16 (1.7) 107 (1.8)
None (N, %) 468 (20.5) 178 (13.3) 191 (13.7) 109 (11.6) 946 (15.9)
Region: Europe
Number of patients 4866 (100.0) 4090 (100.0) 2911 (100.0) 1754 (100.0) 13 621 
(100.0)
NOAC (N, %) 2598 (53.4) 2308 (56.4) 1899 (65.2) 1330 (75.8) 8135 (59.7)
On NOACs standard dose (N, %)
Yes 1523 (31.3) 1514 (37.0) 1373 (47.2) 1016 (57.9) 5426 (39.8)
No 1075 (22.1) 794 (19.4) 526 (18.1) 314 (17.9) 2709 (19.9)
On NOACs reduced dose (N, %)
Yes 1075 (22.1) 794 (19.4) 526 (18.1) 314 (17.9) 2709 (19.9)
No 1523 (31.3) 1514 (37.0) 1373 (47.2) 1016 (57.9) 5426 (39.8)
VKA (N, %) 1728 (35.5) 1367 (33.4) 741 (25.5) 295 (16.8) 4131 (30.3)
No OAC (N, %) 540 (11.1) 415 (10.1) 271 (9.3) 129 (7.4) 1355 (9.9)
ASA (N, %) 280 (5.8) 228 (5.6) 115 (4.0) 66 (3.8) 689 (5.1)
Antiplts other than ASA (N, %) 43 (0.9) 36 (0.9) 22 (0.8) 4 (0.2) 105 (0.8)
None (N, %) 217 (4.5) 151 (3.7) 134 (4.6) 59 (3.4) 561 (4.1)
Region: North America
Number of patients 1458 (100.0) 2045 (100.0) 1593 (100.0) 1258 (100.0) 6354 (100.0)
NOAC (N, %) 714 (49.0) 1215 (59.4) 1093 (68.6) 930 (73.9) 3952 (62.2)
On NOACs standard dose (N, %)
Yes 599 (41.1) 1033 (50.5) 943 (59.2) 772 (61.4) 3347 (52.7)
No 115 (7.9) 182 (8.9) 150 (9.4) 158 (12.6) 605 (9.5)
On NOACs reduced dose (N, %)
Yes 115 (7.9) 182 (8.9) 150 (9.4) 158 (12.6) 605 (9.5)
No 599 (41.1) 1033 (50.5) 943 (59.2) 772 (61.4) 3347 (52.7)
VKA (N, %) 422 (28.9) 442 (21.6) 216 (13.6) 152 (12.1) 1232 (19.4)
No OAC (N, %) 322 (22.1) 388 (19.0) 284 (17.8) 176 (14.0) 1170 (18.4)
ASA (N, %) 200 (13.7) 262 (12.8) 200 (12.6) 134 (10.7) 796 (12.5)
Antiplts other than ASA (N, %) 4 (0.3) 21 (1.0) 5 (0.3) 4 (0.3) 34 (0.5)
None (N, %) 118 (8.1) 105 (5.1) 79 (5.0) 38 (3.0) 340 (5.4)
Region: Latin America
Number of patients 361 (100.0) 420 (100.0) 284 (100.0) 439 (100.0) 1504 (100.0)
NOAC (N, %) 201 (55.7) 219 (52.1) 164 (57.7) 312 (71.1) 896 (59.6)
(Continues)
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corresponding interval changes for Europe, North America, and Latin 
America were +22.2%, +25.8%, and +14.2%. The interval changes in 
those with CHA2DS2- VASc scores ≥2 who received VKAs in Asia were 
−17.5%. The corresponding interval changes for Europe, North America, 
and Latin America were −18.5%, −17.2%, and −15.3% (Table S2).
3.3 | Prescription of antithrombotics over time by 
HAS- BLED score class
Regional patterns of prescription of antithrombotic drugs over time by 
HAS- BLED score class are presented in Table S3. The interval changes 
in those with HAS- BLED scores ≥3 who received NOACs in Asia were 
+4.1%. The corresponding interval changes for Europe, North America 
and Latin America were +20.7, +20.3, and +22.5%. The interval changes 
in those with HAS- BLED scores ≥3 who received VKAs in Asia were 
−9.7%. The corresponding interval changes for Europe, North America, 
and Latin America were −18.5%, −17.2%, and −21.3% (Table S4).
4  | DISCUSSION
We found that use of NOAC increased and VKA decreased over time 
in patients with newly diagnosed AF. In consecutive years after their 
introduction, the proportions of patients prescribed NOAC increased 
and exceeded that of VKA or no OAC in all geographical regions, just 
as prescriptions for VKA decreased in all regions. North America was 
associated with NOAC prescription in the univariate analysis of NOAC 
vs. VKA prescription. The interval changes between fourth and first 
year after NOAC approval regarding NOAC prescription in patients 
with CHA2DS2- VASc scores ≥2 were the highest in Asia and North 
America. The interval changes between fourth and first year after 
NOAC approval regarding NOAC prescription in patients with HAS- 
BLED score ≥3 were the highest in Latin America, Europe, and North 
America. The prescription of non- OAC agents decreased in Asia, 
Europe, and North America but remained little changed in Latin 
America.
The use of NOAC appears to have increased over time in Europe. 
This finding is consistent with other reports.7- 9 After the release of 
NOAC, the prevalence of NOAC use rose steadily in Japan.10 Similar 
patterns of NOAC and VKA prescription were shown in Outcomes 
Registry for Better Informed Treatment of Atrial Fibrillation 
(ORBIT- AF).11
Smaller proportions of patients from Latin America were 
prescribed NOAC or VKA at baseline in the Global Anticoagulant 
Registry in the Field- Atrial Fibrillation (GARFIELD- AF) than in 
our registry.12 Patients prescribed VKA during the last year 
of enrolment were more likely to have concomitant diseases, 
such as CHF, diabetes or vascular disease, than those who use 
NOAC during their last year of enrolment in Europe. In other 
studies, patients prescribed VKAs also had more comorbidities 
than those prescribed NOACs.13- 14 Similar to our study, pa-
tients prescribed VKA were more likely to have permanent AF 
than those prescribed NOAC in each region.13- 14 Interestingly, 
in Korean patients those who used VKAs were less likely to 
have prior stroke/TIA/systemic embolism than those who 
used NOACs.15
In our study, the proportion of patients who were prescribed a 
reduced dose of NOAC is highest in Asia, a finding that could be re-
lated to smaller body size in Asian patients. The risk of major bleed-
ing seems to be higher in Asian patients medicated with VKAs than 
in non- Asian patients.16 In one study, lower NOAC doses were fre-
quently used in Asian patients in routine daily practice. However, 
unjustified underdosing of apixaban was associated with a less ap-
parent clinical benefit over warfarin in patients.17
The data from baseline Phase II of GLORIA- AF showed that 
considerable numbers of patients were not treated with OAC, es-
pecially in Asia and North America.18 Our observations are concor-
dant with other studies in the United States, Denmark, Australia, 
and Korea.15,19- 21 However, data from the United States (from 
Year 1 Year 2 Year 3 Year 4 Total
On NOACs standard dose (N, %)
Yes 122 (33.8) 112 (26.7) 83 (29.2) 142 (32.3) 459 (30.5)
No 79 (21.9) 107 (25.5) 81 (28.5) 170 (38.7) 437 (29.1)
On NOACs reduced dose (N, %)
Yes 79 (21.9) 107 (25.5) 81 (28.5) 170 (38.7) 437 (29.1)
No 122 (33.8) 112 (26.7) 83 (29.2) 142 (32.3) 459 (30.5)
VKA (N, %) 117 (32.4) 137 (32.6) 73 (25.7) 78 (17.8) 405 (26.9)
No OAC (N, %) 43 (11.9) 64 (15.2) 47 (16.5) 49 (11.2) 203 (13.5)
ASA (N, %) 24 (6.6) 46 (11.0) 33 (11.6) 31 (7.1) 134 (8.9)
Antiplts other than ASA (N, %) 3 (0.8) 4 (1.0) 3 (1.1) 3 (0.7) 13 (0.9)
None (N, %) 16 (4.4) 14 (3.3) 11 (3.9) 15 (3.4) 56 (3.7)
Note: Standard dose: Dabigatran 150- mg BID, Rivaroxaban 20- mg QD, Apixaban 5- mg BID, Edoxaban 60- mg QD. The other doses are reduced.
Abbreviations: ASA, acetylsalycylic acid, NOAC, non- vitamin K antagonist oral anticoagulants, VKA, Vitamin K antagonists.
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(95% CI) for NOAC 
prescription
Multivariate analysis 
relative proportion (95% CI) 
for NOAC prescription
Time (categorical, Years 1- 4)
Year 1 7040 4179 (59.4) 2861 (40.6) 1.0 (ref) 1.0 (ref)
Year 2 6573 4361 (66.3) 2212 (33.7) 1.118 (1.09- 1.15) 1.10 (1.07- 1.12)
Year 3 5043 3683 (73.0) 1360 (27.0) 1.23 (1.20- 1.26) 1.20 (1.17- 1.23)
Year 4 3759 3142 (83.6) 617 (16.4) 1.41 (1.38- 1.44) 1.34 (1.31- 1.37)
Region
Asia 3664 2382 (65.0) 1282 (35.0) 0.98 (0.95- 1.01) 1.03 (0.99- 1.05)
Europe 12 266 8135 (66.3) 4131 (33.7) 1.0 (ref) 1.0 (ref)
North America 5184 3952 (76.2) 1232 (23.8) 1.15 (1.13- 1.17) 1.05 (1.03- 1.08)
Latin America 1301 896 (68.9) 405 (31.1) 1.04 (0.99- 1.08) 0.99 (0.96- 1.04)
BMI class
<18.5 297 201 (67.7) 96 (32.3) 0.99 (0.92- 1.09) 0.98 (0.91- 1.05)
18.5- 24 5856 3970 (67.8) 1887 (32.2) 1.0 (ref) 1.0 (ref)
25- 29 8623 5884 (68.2) 2738 (31.8) 1.01 (0.98- 1.03) 1.00 (0.98- 1.02)
30- 34 4582 3165 (69.1) 1417 (30.9) 1.02 (0.99- 1.05) 0.99 (0.97- 1.01)
≥35 3057 2145 (70.2) 912 (29.8) 1.04 (1.01- 1.07) 0.98 (0.96- 1.01)
Categorization of AF
Symptomatic 6996 4740 (67.8) 2256 (32.2) 0.96 (0.94- 0.98) 0.98 (0.96- 0.99)
Minimally symptomatic 7915 5332 (67.4) 2583 (32.6) 0.96 (0.94- 0.98) 0.99 (0.97- 1.00)
Asymptomatic 7504 5293 (70.5) 2211 (29.5) 1.0 (ref) 1.0 (ref)
HAS- BLED score <3 20 619 14 176 (68.8) 6443 (31.2) 1.0 (ref) 1.0 (ref)
HAS- BLED score ≥3 1796 1189 (66.2) 607 (33.8) 0.96 (0.93- 0.99) 0.96 (0.93- 0.99)
CHA2DS2- VASc score =1 2741 1902 (69.4) 839 (30.6) 1.0 (ref) 1.0 (ref)
CHA2DS2- VASc score ≥2 19 674 13 463 (68.4) 6211 (31.6) 0.99 (0.96- 1.01) 0.97 (0.95- 0.99)
Chronic gastrointestinal 
disease
Yes 2968 2101 (70.8) 867 (29.2) 1.04 (1.01- 1.06) 1.01 (0.99- 1.03)
No 19 447 13 264 (68.2) 6183 (31.8) 1.0 (ref) 1.0 (ref)
Type of AF
Paroxysmal 11 828 8536 (72.2) 3292 (27.8) 1.0 (ref) 1.0 (ref)
Persistent 8239 5304 (64.4) 2935 (35.6) 0.89 (0.88- 0.91) 0.93 (0.92- 0.95)
Permanent 2348 1525 (64.9) 823 (35.1) 0.90 (0.87- 0.93) 0.93 (0.90- 0.96)
Type of site
GP/primary care 1123 830 (73.9) 293 (26.1) 1.282 (1.230- 1.334) 1.24 (1.19- 1.29)
Specialist office 6945 5199 (74.9) 1746 (25.1) 1.29 (1.27- 1.33) 1.22 (1.19- 1.25)
Community hospital 7205 5171 (71.8) 2034 (28.2) 1.25 (1.21- 1.28) 1.23 (1.20- 1.27)
University hospital 6540 3769 (57.6) 2771 (42.4) 1.0 (ref) 1.0 (ref)
Other 602 396 (65.8) 206 (34.2) 1.14 (1.07- 1.21) 1.15 (1.09- 1.22)
Cancer
Yes 2261 1586 (70.1) 675 (29.9) 1.026 (0.99- 1.06) 0.99 (0.97- 1.02)
No 20 154 13 779 (68.4) 6375 (31.6) 1.0 (ref) 1.0 (ref)
(Continues)
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2008 to 2014) indicate no increase in OAC prescriptions overall 
due to an increase in NOAC uptake being offset by a decrease in 
VKA use.22
In our analysis, the prescription of NOAC for stroke prevention 
has been increasingly associated with individual patient stroke risk as 
recommended by the European Society of Cardiology guidelines.23 
The proportion of patients on OAC increased with CHA2DS2- VASc 
score, as described in other datasets.24
Increased prescription of NOAC over the 4 years of enrollment in 
GLORIA- AF is consistent with other reports.15,20,25 The proportion of 
patients with moderate- to- high risk of stroke who are not prescribed 
OAC has declined continuously. Increased awareness of physicians 
and patients, improved implementation of guidelines, and educa-
tional programs might have resulted in greater NOAC prescription.26 
Indeed, noticeable differences in patients' baseline characteristics be-
tween consecutive years of enrolment are evident. The use of NOAC 
has also been increasing among patients with higher bleeding risk.
This study has important practical implications and may help in 
identifying the “action points” needed to improve stroke prevention 
in AF patients in “routine” clinical practice. Our observations also 
reflect the evolution of international guidelines on the management 
of AF in clinical practice.27
Numerous registries have reported data on prescription patterns of 
antithrombotics for stroke prevention in AF, but comparison across reg-
istries appears to be challenging for a variety of reasons. The GLORIA- AF 
registry's specific design facilitated a description of how the OAC pre-
scription patterns changed across participating countries after NOAC ap-
proval. In contrast, in the EURObservational Research Programme (EORP) 
and the GARFIELD- AF registries, temporal OAC prescription patterns 
were presented by calendar year, which led to an aggregation of coun-
tries with and without NOAC approval particularly in the first years of 
NOAC availability; ie, while the first NOAC, dabigatran, was approved in 
the United States in 2011, the first approval in Italy only occurred in 2013; 
therefore, country composition as well as the amount patients by country 
had an impact on the observed treatment patterns. aggregated.7,25
In our study, that only started with NOACs availability, the propor-
tion of patients prescribed NOAC increased within a period of between 1 
and 4 years, while the proportions of VKA and no- OAC prescriptions de-
creased. A pattern similar to that in our study has also been seen in other 
studies,25 with a decline in the use of VKA as well as antiplatelets, and a 
rise in the use of NOAC. In the EORP- AF registry 7, most of patients who 
were medicated with VKA or NOAC at the baseline and at 1- year fol-
low- up were still anticoagulated with the same OAC at 2- year follow- up.
In this study, patients with a high HAS- BLED score had a 
generally increasing proportion of OAC prescriptions between 
the first and fourth year of enrollment. The percentage of pa-
tients with no OAC among patients with HAS- BLED score ≥3 
was relatively stable (approximately one third of the patients) 
over the same period. A high percentage of patients with HAS- 
BLED score ≥3 had no OAC prescription, possibly reflecting a 
lack of concordance between empirical bleeding scores and 
physician assessment of bleeding risk in AF.28 Importantly, there 
appears to be a need to emphasize that AF patients with a high 
risk of bleeding should continue taking OAC with close monitor-
ing and frequent visits and individual reassessment of thrombo-
embolic and bleeding risks.23,29- 30 In the mobile atrial fibrillation 
application (mAFA- II) randomized trial, proactive use of HAS- 
BLED for dynamic bleeding risk assessment was associated with 
lower bleeding rates and an increase in OAC use.31
Furthermore, year of enrolment, type of site, region, type and cat-
egorization of AF, and stroke and bleeding risks are associated with 
NOAC prescription in the combined Phase II and III data in our anal-
ysis. A similar pattern was found in another report where persistent 
or permanent AF was inversely associated with NOAC prescription.13 
Also, the year of enrollment was associated with NOAC prescription.
4.1 | Limitations
These findings may not generalize to the entire global nonvalvular 
AF patient population or even to the patient population of the par-
ticipating countries, because the study is restricted to patients with 
a CHA2DS2- VASc score ≥1. Furthermore, this analysis represents 
only a snapshot of the prescribing practice in the course of treat-
ment and does not take into account treatment continuation, switch-
ing or adherence. These issues were addressed in other reports from 











(95% CI) for NOAC 
prescription
Multivariate analysis 




Self- pay/no overage 1362 894 (65.6) 467 (34.3) 0.956 (0.92- 0.99) 0.99 (0.96- 1.03)
Not self- pay 21 053 14 471 (68.7) 6583 (31.3) 1.0 (ref) 1.0 (ref)
Abbreviations: AF, atrial fibrillation; BMI, body mass index; CHA2DS2- VASc, congestive heart failure, hypertension, age ≥75 years, diabetes, 
stroke/transient ischemic attack/systemic embolism, vascular disease, age 65- 74 years, sex category (female); CI, confidence interval; GP, general 
practitioner; HAS- BLED, hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile international normalized ratio, 
elderly (>65 years), drugs or alcohol concomitantly; NOAC, nonvitamin K antagonist oral anticoagulants; ref, reference; VKA, Vitamin K antagonist.
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5  | CONCLUSIONS
In this global registry of prospectively enrolled AF patients, 
NOACs have been more commonly prescribed than VKA. During 
4 years after approval of the first NOAC for stroke prevention 
in AF, NOAC use increased over time, while VKA use decreased 
across all regions.
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